Sprott Inc. Gain Therapeutics, Inc. Transaction History
Sprott Inc.
- $1.58 Billion
- Q1 2025
A detailed history of Sprott Inc. transactions in Gain Therapeutics, Inc. stock. As of the latest transaction made, Sprott Inc. holds 14,000 shares of GANX stock, worth $24,780. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,000
Previous 14,000
-0.0%
Holding current value
$24,780
Previous $28,000
7.14%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding GANX
# of Institutions
37Shares Held
3.52MCall Options Held
8.4KPut Options Held
8.7K-
David Einhorn Greenlight Capital Inc | New York, Ny588KShares$1.04 Million0.1% of portfolio
-
Dme Capital Management, LP New York, NY566KShares$1 Million0.05% of portfolio
-
Jones Financial Companies Lllp428KShares$757,0290.0% of portfolio
-
Geode Capital Management, LLC Boston, MA282KShares$499,5130.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA255KShares$451,3320.0% of portfolio
About Gain Therapeutics, Inc.
- Ticker GANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,883,400
- Market Cap $21M
- Description
- Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...